La Paz University HospitalMadrid, Spain
I have nothing to disclose
1465: Sustainability of Clinical Response Through 2 Years Among Upadacitinib-Treated Patients With Axial Spondyloarthritis: Data From the SELECT-AXIS 1 and SELECT-AXIS 2 Trials
Monday, October 27, 202510:30 AM - 12:30 PM Central Time
Disclosure(s): Alfasigma: Advisor or Review Panel Member (Ongoing)
